

# ASX Release

## Top 20 Shareholders

**PERTH, AUSTRALIA – 14 August 2018:** SUDA Pharmaceuticals Ltd (ASX: SUD), hereby provides an update of the top 20 shareholders at 13 August 2018.

Rank	Holder Name	Number of Shares	% Held
1	CS THIRD NOMINEES PTY LIMITED	100,000,000	3.87
2	KAMALA HOLDINGS PTY LTD	82,300,000	3.19
3	ZERRIN INVESTMENTS PTY LTD	73,178,667	2.83
4	SCINTILLA STRATEGIC INVESTMENTS LIMITED	50,000,000	1.94
5	MR THOMAS MCGELLIN + MS TANYA KARAL	48,814,323	1.89
6	BILL BROOKS PTY LTD	47,431,261	1.84
7	CHELSEA INVESTMENTS (WA) PTY LTD	47,320,698	1.83
8	BAMBER INVESTMENTS PTY LTD	46,446,552	1.80
9	TERMCO PTY LTD	34,453,333	1.33
10	BANLAN PTY LTD	34,127,469	1.32
11	MR JAMES RICHARDSON	32,145,086	1.24
12	ONICAS INVESTMENTS PTY LTD	30,000,000	1.16
13	MR PETER NORMAN DUNN	30,000,000	1.16
14	MR BIN LIU	25,000,000	0.97
15	MS CHUNYAN NIU	25,000,000	0.97
16	MR STEVE JOHN WICKS	24,959,364	0.97
17	FOSKIN PTY LTD	24,470,813	0.95
18	J P MORGAN NOMINEES AUSTRALIA LIMITED	24,006,426	0.93
19	MS GIOVANNALINA GAN	23,000,000	0.89
20	MR NEIL STEWART + MRS JANET STEWART	21,533,333	0.83
		<b>824,187,325</b>	<b>31.91</b>



**Further information:**  
**STEPHEN CARTER**  
**CHIEF EXECUTIVE OFFICER/MANAGING DIRECTOR**  
**SUDA Pharmaceuticals Ltd**  
Tel: +61 8 6142 5555  
[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

**NOTES TO EDITORS:****About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. ZolpiMist is partnered with Eddingpharm in China and Teva Pharmaceuticals in Latin America. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit [www.sudapharma.com](http://www.sudapharma.com)